Santosh Mahil Appointed CEO of Sekhmet Pharmaventures Backed by PAG, CX Partners, and Samara Capital

Santosh Mahil has been appointed as the Chief Executive Officer of Sekhmet Pharmaventures, an India-based API (Active Pharmaceutical Ingredient) investment platform. The company is backed by prominent investment firms PAG, CX Partners, and Samara Capital. Mahil will oversee operations and lead strategic initiatives for the organization as it continues to expand its presence in the pharmaceutical sector.

Sekhmet Pharmaventures focuses on investments within the API industry, a critical component of pharmaceutical manufacturing. The appointment comes as part of the company’s efforts to strengthen leadership and drive growth in this specialized field. Backed by PAG, CX Partners, and Samara Capital—well-known entities in private equity—the platform aims to leverage their expertise and resources under Mahil’s leadership to further its objectives in the Indian market.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 5, 2025

Related posts:

Generic Drug Stability Testing Follows FDA Guidelines to Ensure Medication Quality and Safety Teenage years crucial for depression intervention, study finds Rilonacept Targets IL-1 Pathways to Manage Recurrent Pericarditis Metsera Reports Four-Week Effect from Single Injection in Early Obesity Treatment Study

Author

Mark Chiang